BioCryst (BCRX) Q2 2023: Orladeyo Paid Rate Falls to 30% as Patient Growth Drives $81M Revenue Step-Up

August 3, 2023 | By EarningsIQ Research

BioCryst’s Q2 saw a material revenue jump, powered by linear patient growth and improved conversion of Orladeyo users to paid therapy. The company is methodically reducing free product reliance and tightening operating discipline, while pipeline updates point to risk-managed R&D allocation. Steady execution but no inflection in ex-U.S. growth or pipeline risk reduction—investors should watch for continued progress in paid conversion and pivotal trial clarity into 2024.

Summary

• Paid Therapy Conversion: Orladeyo’s paid patient rate improved, but the free drug burden remains a multi-year challenge.
• Pipeline Discipline: R&D investment is tightly controlled, with pivotal trial acceleration contingent on best-in-class data.
• Global Expansion: Ex-U.S. launches are progressing, but revenue contribution remains modest and linear.

Business Overview

BioCryst Pharmaceuticals develops and commercializes oral therapies for rare diseases, with its flagship product Orladeyo, an oral, once-daily prophylactic for hereditary angioedema (HAE), accounting for the vast majority of revenue. The company’s business model centers on capturing market share in established and new geographies, converting patients from injectable and other prophylactic regimens, and investing in a pipeline of structure-based drug discovery programs targeting rare disease indications. Major segments include U.S. commercial sales (about 90% of revenue), ex-U.S. launches, and an early-stage R&D pipeline.

Performance Analysis

Q2 delivered a pronounced revenue step-up for Orladeyo, with global sales reaching $81 million, up 24% YoY in the U.S. and 26% ex-U.S. This surge stems from both steady, linear patient growth and improved execution in converting patients from free drug to paid therapy. The percentage of patients on free product declined from 34% at the start of the year to 30% by quarter-end, a meaningful improvement given each percentage point shift equates to roughly $4 million in annual revenue.

Operating expenses (excluding non-cash stock comp) were flat YoY at $90.4 million, reflecting disciplined spend as R&D investment trends lower versus 2022. Net operating cash utilization improved materially, dropping to $13 million from $28 million in the prior year quarter, driven by higher revenues and stable cost structure. U.S. sales still comprise about 90% of global revenue, but ex-U.S. launches are steadily contributing, with the company targeting 20% of peak sales internationally over the long term.

• Patient Growth Consistency: U.S. net patient adds remained linear, with retention rates stable and discontinuation rates declining as the base grows.
• Free-to-Paid Conversion: Commercial team progress in paperwork completion and payer engagement is driving incremental paid therapy conversion, a key lever for revenue expansion.
• Cash and Capital: Cash balance at quarter-end was $415.7 million, bolstered by a refinancing that extends debt maturity to 2028 and improves capital flexibility.

While growth is robust, the revenue model’s dependence on ongoing patient conversion and U.S. reimbursement dynamics remains a central risk and opportunity. Ex-U.S. revenue, though growing, is not yet a scale driver.

Executive Commentary

Strategic Positioning

1. U.S. Market Penetration and Paid Therapy Focus

BioCryst’s top commercial priority is converting Orladeyo users from free to paid therapy, especially within the commercially insured segment, which represents over 60% of the U.S. business. The company is leveraging improved paperwork completion, appeals, and education to drive payer approvals. Each incremental paid patient delivers high-margin revenue, reinforcing the importance of this operational lever.

2. International Expansion Remains Linear

Ex-U.S. launches are tracking a steady, grind-higher trajectory rather than inflection, with patient adds and country launches expected to continue incrementally. The company targets 20% of peak global sales from non-U.S. markets, but acknowledges it takes about four ex-U.S. patients to equal the revenue of one U.S. patient, underscoring the relative weight of domestic execution.

3. Pipeline Investment Discipline

R&D allocation is governed by a “best-in-class or stop” approach, with pivotal trial acceleration for BCX10013 (oral factor D inhibitor) contingent on data showing clear superiority or parity to competitive options. Early data in healthy volunteers is promising, but chronic toxicology and dose-ranging trials in patient populations are required before further investment. This approach diversifies risk across multiple programs but avoids escalating spend without strong proof-of-concept.

4. Patient and Prescriber Activation

Patient activation efforts, including participation in large patient summits and expanded patient services, are intended to increase awareness and trial among both prophy-naive and switch patients. The Salesforce and support teams are sized to match market opportunity and are perceived as highly active by prescribers, supporting both depth and breadth of market penetration.

5. Margin and Cash Flow Management

Flat operating expenses and improved net cash utilization reflect a conservative financial posture, providing optionality for pipeline investment and commercial expansion while protecting downside risk if revenue conversion lags.

Key Considerations

This quarter’s results highlight BioCryst’s methodical execution, but also the multi-year nature of its key growth levers and the importance of disciplined R&D risk-taking. Investors should focus on:

Key Considerations:

• Free Drug Drag: The 30% free product rate remains a significant revenue headwind, though incremental progress is visible; full resolution is a multi-year process.
• Retention and Patient Mix: Retention rates are stable, with a consistent 60% one-year retention and a balanced mix of switch and prophy-naive patients driving growth.
• Pipeline Clarity Needed: Pivotal trial commitment for BCX10013 and other assets will depend on 2024 clinical data; until then, pipeline optionality is high but visibility is low.
• Ex-U.S. Revenue Leverage: International launches add diversification but are unlikely to materially shift the revenue mix near-term.
• Gross-to-Net Normalization: Q2 saw gross-to-net return to the lower end of the 15%-20% range after Q1 seasonality, supporting margin stability for the remainder of the year.

Risks

BioCryst faces persistent risks from payer reimbursement dynamics, as the pace of paid therapy conversion is not fully under management’s control and could be disrupted by changes in insurance or co-pay assistance. Pipeline risk is elevated, with pivotal investment for BCX10013 contingent on forthcoming clinical data; failure to demonstrate best-in-class safety and efficacy would halt development and limit future growth options. Ex-U.S. launches, while diversifying, offer lower revenue per patient and are exposed to local regulatory and market access hurdles.

Forward Outlook

For Q3, BioCryst guided to:

• Continued linear patient growth driving steady revenue increases
• Incremental progress in paid therapy conversion, with free drug rate expected to decline further

For full-year 2023, management reiterated guidance:

• No less than $320 million in global Orladeyo revenue
• Flat operating expenses at $375 million

Management highlighted several factors that will drive results:

• Q3 and Q4 revenue will reflect steady patient adds, without a Q2-like step-up
• R&D day in November will provide visibility into new pipeline programs and data

Takeaways

BioCryst’s Q2 confirms linear execution in the core Orladeyo business, with meaningful but gradual progress on paid therapy conversion and disciplined cost management. Pipeline optionality remains, but pivotal commitment awaits 2024 data.

• Revenue Expansion Hinges on Paid Conversion: The company’s ability to convert free drug patients to paid status is the single most important lever for near-term growth and margin improvement.
• Pipeline Remains a “Show Me” Story: R&D discipline is commendable, but investors will need to see best-in-class data before underwriting future value from BCX10013 or other assets.
• International Growth Will Be Incremental: Ex-U.S. launches add diversification but are unlikely to dramatically shift revenue or profit mix in the next year.

Conclusion

BioCryst’s Q2 demonstrates solid operational execution and prudent financial management, but the company’s long-term value will be determined by its success in converting Orladeyo patients to paid therapy and delivering pivotal pipeline data. Investors should watch for continued progress on both fronts as the company targets $1 billion in peak sales by decade’s end.

Industry Read-Through

BioCryst’s experience underscores two persistent themes in rare disease commercialization: the slow, steady nature of patient and prescriber activation, and the critical importance of payer dynamics in determining revenue capture. Companies with oral therapies that can displace injectables will continue to face multi-year conversion cycles, and gross-to-net management remains a key determinant of profitability. Pipeline investment discipline, with a focus on “best-in-class or stop,” is likely to become more prevalent as investors demand clear proof before funding late-stage trials. Ex-U.S. expansion in rare diseases offers diversification but rarely delivers rapid scale, reinforcing the primacy of U.S. execution for commercial-stage biotech firms.

BCRX Healthcare Biotechnology Rare Disease Oral Therapy Pipeline Reimbursement Commercialization